UCB's Global Corporate Website

This section is intended for media and financial analysts

Our Shareholders

Since 13 March 2014, UCB’s capital amounts to € 583 516 974, divided in 194 505 658 ordinary shares with no nominal value.

The main shareholder of UCB is Financière de Tubize SA, a Belgian company listed on Euronext Brussels.

Shareholder Structure

Source

Latest notifications and shareholder identification (as of January 2023), UCB underlying ownership analysis

close

62% Free Float

Institutional investors:
Geographic distribution

Shareholders' Meetings

The Ordinary General Meeting of Shareholders is held on the last Thursday of April at 11:00 CET.

The next shareholders' meeting takes place on

25 April 2024

Shareholders' Meeting Archives


 


 

Consensus

Estimates based on Visible Alpha consensus1 dated 31.05.2023.

Estimates include 11 broker models2.

UCB FY Consensus Earnings Estimates (Average)
In € million 2022a 2023e 2024e 2025e  2026e 2027e 2028e
Net Sales 5,140 4,969 5,447 6,092 6,481 6,836 7,134
Revenue 5,517 5,298 5,755 6,399 6,789 7,126 7,469
Adjusted EBIT 675 658 970 1,452 1,642 1,814 1,917
Adjusted EBITDA 1,260 1,216 1,549 2,033 2,231 2,393 2,485
Adj. EBITDA ratio 22.8% 22.9% 26.9% 31.8% 32.9% 33.6% 33.3%
Net Profit 418 369 649 1,092 1,249 1,348 1,421
Core EPS (€) 4.37 3.74 5.35 7.83 8.83 9.47 9.77
UCB FY Consensus Product Sales Estimates (Average)
In € million 2022a 2023e 2024e 2025e  2026e  2027e  2028e
Product Portfolio              
Cimzia 2,085 2,027 1,927 1,771 1,482 1,240 1,053
Bimzelx 35 188 555 1,043 1,541 2,024 2,494
Evenity* 25 54 95 128 158 180 193
Vimpat 1,124 576 447 363 304 280 246
Keppra 729 590 520 476 438 408 392
Briviact 485 568 641 703 572 398 337
Neupro 305 272 239 210 193 178 160
Fintepla 116 249 395 528 657 759 714
Nayzilam 78 100 119 137 141 147 128
Potential New Products non-risk adjusted        
Rozanolixizumab    26 87 186 331 445 556
Zilucoplan   24 168 291 504 661 819
Dapirolizumab pegol     25 64 120 212 302
Staccato alprazolam     21 41 87 129 141
Bepranemab         5 120 194
UCB0599         15 120 236
doxTM / MT1621   5 16 40 81 113 127

*European sales, ex-EU sales booked by Amgen/Astellas

1Disclaimer

The information provided by Visible Alpha cited herein provided “as is” and “as available” without warranty of any kind. Use of any Visible Alpha data is at your own risk and Visible Alpha disclaims any liability for use of the Visible Alpha data.
Although the information is obtained or compiled from reliable sources Visible Alpha neither can nor does guarantee or make any representation or warranty, either express or implied, as to the accuracy, validity, sequence, timeliness, completeness or continued availability of any information or data, including third-party content, made available herein.
In no event shall Visible Alpha be liable for any decision made or action or inaction taken in reliance on any information or data, including third-party content. Visible Alpha further explicitly disclaims, to the fullest extent permitted by applicable law, any warranty of any kind, whether express or implied, including warranties of merchantability, fitness for a particular purpose and non-infringement.

close

2Contributing brokers

Broker Model date
Berenberg 06-Mar-2023
BNPP Exane 28-Feb-2023
BofA 23-Feb-2023
Cowen 22-Feb-2023
DB 23-Feb-2023
ING  
Jefferies 09-May-2023
Kepler Cheuvreux 27-Feb-2023
MS 07-Mar-2023
ODDO 01-Mar-2023
Redburn 26-May-2023

 

close

 

Dividends

The Board intends to continue to sustain a dynamic dividend policy, consistent with the long-term growth prospects of the Company, offering gradual increase in dividend, and as far as possible not to reduce it, irrespective of the short-term income variations.

The Board of Directors proposed to pay a gross dividend of € 1.33 per share (gross), which was approved by the annual general meeting of the shareholders.

  • Coupon # 26
  • Ex-dividend: 28 April 2023
  • Record date: 2 May 2023
  • Payment: 3 May 2023

Coupon # 26 of UCB shares is payable at € 0.931 net per share after deduction of Belgian withholding tax of 30%*, via our paying agent, KBC Bank NV.

* Lower withholding tax rates may be applicable depending on the specific situation of each shareholder.